Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily used for managing type 2 diabetes, whereas Wegovy is specifically approved for weight loss.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly higher for patients without versus with type 2 diabetes (64.8% vs 46.5%), reported Ezekiel J. Emanuel, MD, PhD, of the University of Pennsylvania in Philadelphia, and colleagues.

Weight-loss drugs are transforming both health care and Wall Street, with leading manufacturers like Eli Lilly & Co. (LLY) and Novo Nordisk A/S (NVO) seeing stock prices soar. These medications are reshaping a health care market that serves the 40% of U.

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), widely used medications for managing type 2 diabetes and obesity,

Australia's agriculture sector is poised for a strong year, but the Trump presidency, global conflicts and anti-obesity medications are creating uncertainty.

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects